Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (NYSE: KVUE) is recognized as the world's largest pure-play consumer health company, boasting an impressive annual revenue of $15 billion. Established as an independent entity in May 2023 after its spin-off from Johnson & Johnson's consumer segment, Kenvue has rapidly distinguished itself in the market. The company's diverse portfolio spans across several key sectors within the consumer health industry, including cough, cold, and allergy care, pain management, face and body care, oral care, and women's health.
Some of the most iconic brands under Kenvue's umbrella include Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. These brands hold significant market positions globally, attributed to their strong brand equity and consumer trust. Despite operating in a highly fragmented and competitive industry, Kenvue's commitment to quality and innovation has kept it ahead of the curve.
Recently, Kenvue has made strides in its environmental, social, and governance (ESG) initiatives. In May 2024, the Science Based Targets initiative (SBTi) validated Kenvue's near-term greenhouse gas (GHG) emissions reduction targets, aligning with the goal to limit global temperature rise to 1.5°C. This validation underscores Kenvue's dedication to sustainability and its mission to advance the well-being of both people and the planet through its Healthy Lives Mission.
Financially, Kenvue maintains a robust position with a clear focus on expanding its product lines and market reach. The company continues to invest in research and development to enhance its product offerings. Strategic partnerships and collaborations are also central to Kenvue's growth strategy, further solidifying its presence in the consumer health sector.
For the latest updates and information on Kenvue's performance, current projects, and recent achievements, investors and stakeholders are encouraged to visit the company's official website and review its filings with the Securities and Exchange Commission.
Neutrogena®, part of Kenvue Inc. (NYSE: KVUE), announced multi-year partnerships with dermatologists Dr. Dhaval Bhanusali and Dr. Muneeb Shah to enhance its dermatological beauty offerings. As Global Innovation Partners, they will focus on three key areas: innovation acceleration, consumer engagement, and dermatologist collaboration. The partnership aims to advance clinical science, improve product experience, and build consumer community engagement. This initiative reinforces Neutrogena's position as America's #1 facial skincare brand and strengthens its commitment to combining beauty with scientific innovation.
Starboard Value LP, an investment adviser, announced that its CEO Jeffrey Smith presented at the 2024 Active-Passive Investor Summit. The presentation highlighted value creation opportunities at three companies: Kenvue Inc. (NYSE: KVUE), Pfizer Inc. (NYSE: PFE), and Salesforce Inc. (NYSE: CRM).
The full presentation and individual company presentations are available on Starboard's website. Starboard Value LP focuses on investing in deeply undervalued companies and actively engages with management teams and boards to unlock shareholder value.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has announced it will release its third quarter 2024 financial results on November 7, 2024, before the market opens. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results.
Investors can access the conference call by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast will be available at investors.kenvue.com, with a replay accessible after the event. Kenvue's portfolio includes well-known brands such as Aveeno®, BAND-AID®, Johnson's®, Listerine®, Neutrogena®, and Tylenol®.
Kenvue Inc. (NYSE: KVUE), maker of iconic brands like Aveeno®, Listerine®, Neutrogena®, and Tylenol®, is advancing its climate action strategy through its Healthy Lives Mission. The company has released its first Task Force on Climate-related Financial Disclosures (TCFD) report, enhancing transparency and accountability.
Key progress includes:
- Reducing Scope 1 and 2 greenhouse gas emissions by 26% since 2020
- Increasing renewable electricity usage to 65% of total electricity consumption
- Validating near-term GHG reduction targets by the Science Based Targets initiative (SBTi)
- Increasing use of recyclable or refillable packaging to 71% of its portfolio
- Reducing virgin plastic in packaging by 21%
Kenvue is also engaging suppliers through its Supplier Climate Action Program and participating in various climate-focused coalitions to accelerate progress towards its environmental goals.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company, has announced its participation in the Barclays Global Consumer Staples Conference in Boston. CEO Thibaut Mongon, CFO Paul Ruh, and Chief Growth Officer Charmaine England will engage in a fireside chat on September 5, 2024, at 3:00 p.m. Eastern Time. The session will be available via live webcast on investors.kenvue.com, with a replay accessible afterward.
Kenvue boasts a portfolio of iconic brands including Aveeno®, BAND-AID®, Johnson's®, Listerine®, Neutrogena®, and Tylenol®. These brands are backed by science and recommended by healthcare professionals globally. The company emphasizes its commitment to everyday care and aims to empower consumers through its products.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company, is launching Neutrogena® Collagen Bank™, featuring patented micro-peptide technology. This launch targets the pre-aging skincare market, particularly appealing to Gen Z consumers concerned about early signs of aging.
The product line includes two moisturizers designed to defend and support natural collagen. Key features:
- Micro-peptides 2x smaller than leading anti-aging peptides
- Penetrates 10+ layers under skin surface
- Targets 5 markers critical for skin's firming support matrix
- Formulations for all skin tones and types, suitable for daily use
- Clinically proven to work on 5 early signs of collagen decline
The launch strategy includes an exclusive TikTok Shop debut before wider retail distribution, aiming to reach digitally native Gen Z consumers with an affordable skincare solution.
Kenvue Inc. (NYSE: KVUE) reported its Q2 2024 financial results, showing net sales of $4.0 billion, a 0.3% decrease year-over-year, with organic growth of 1.5%. The company's diluted EPS was $0.03, while adjusted diluted EPS reached $0.32. Kenvue's gross profit margin expanded by 360 basis points to 59.1%, and adjusted gross profit margin increased by 410 basis points to 61.6%. The company took a non-cash charge of $488 million related to the Dr.Ci:Labo® business impairment. Despite challenges, Kenvue reaffirmed its 2024 outlook, projecting net sales growth of 1.0%-3.0% and adjusted diluted EPS between $1.10-$1.20.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company, has announced changes to its Board of Directors. Kathleen M. Pawlus and Kirk L. Perry will join as new independent directors, effective August 15, 2024, and December 1, 2024, respectively. Pawlus, with over 40 years of experience in finance and operations, will serve on the Audit Committee. Perry, currently President and CEO of Circana, brings extensive consumer packaged goods and technology experience and will join the Compensation & Human Capital Committee.
Concurrently, Peter M. Fasolo and Joseph J. Wolk, current Johnson & Johnson executives, will resign from the Board in December 2024. This succession process aligns with Kenvue's commitment to independent Board oversight and follows Johnson & Johnson's divestment of its remaining stake in Kenvue in May 2024. By the 2025 Annual Meeting, Kenvue expects its Board to comprise 11 directors, with 10 being independent.
Kenvue Inc. (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has announced a 2.5% increase in its quarterly dividend. The company's Board of Directors declared a $0.205 per share dividend on Kenvue common stock for the third quarter of 2024. This increase demonstrates Kenvue's commitment to returning cash to shareholders as part of its capital allocation strategy aimed at enabling sustainable growth and optimizing total shareholder return.
The dividend will be payable on August 28, 2024, to shareholders of record as of the close of business on August 14, 2024. Kenvue's portfolio includes iconic brands such as Aveeno®, BAND-AID®, Johnson's®, Listerine®, Neutrogena®, and Tylenol®, which are science-backed and recommended by healthcare professionals worldwide.
Kenvue (NYSE: KVUE), the leading global consumer health company, will release its second-quarter 2024 financial results on August 6, 2024, before the market opens. The results will cover the quarter ending June 30, 2024.
A conference call and webcast will follow at 8:30 a.m. Eastern Time to discuss the results. U.S. participants can dial 877-407-8835, while international participants can dial +1 201-689-8779 to join the call. The webcast will be available on Kenvue's investor relations website, with a replay accessible post-event.
Kenvue, known for brands like Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol, emphasizes the importance of everyday care, with products supported by scientific research and healthcare professionals globally.
FAQ
What is the current stock price of Kenvue (KVUE)?
What is the market cap of Kenvue (KVUE)?
What is Kenvue Inc.?
When did Kenvue go public?
What are some of Kenvue's well-known brands?
What sectors does Kenvue operate in?
What recent achievements has Kenvue made?
What is Kenvue's Healthy Lives Mission?
How does Kenvue approach ESG initiatives?
What is the financial condition of Kenvue?
How can I find more information about Kenvue's financial performance?
Who can I contact for investor relations at Kenvue?
